AOD-9604 in Batrad — Fat Loss Peptide Research Guide
AOD-9604 research guide for Batrad. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
Unlike general health products stocked in every health store, AOD-9604 is distributed via a global research peptide market that Batrad residents navigate through international suppliers. The benefit of this online-only market is that serious vendors compete aggressively on their analytical documentation, giving researchers access to better quality signals than any physical store could provide. A legitimate AOD-9604 supplier's COA should include HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all traceable to your specific batch. Use this guide to evaluate AOD-9604 vendors rigorously — the framework here work regardless of your location.
How AOD-9604 Works — Mechanisms & Research
AOD-9604 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Batrad studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
Where to Buy AOD-9604 — A Researcher's Guide
The most effective path to quality AOD-9604 is engaging research communities before vendor sites — peptide forums track vendor quality over time that are more reliable than search results. The HPLC chromatogram is the most important document in the COA: it should show a large primary peak representing AOD-9604, with small or absent impurity peaks representing impurities — purity should be stated as ≥98%. For Batrad researchers evaluating vendors with limited track records: a modest first purchase to test the product before placing larger orders is what experienced peptide researchers consistently do. The powdered lyophilised form of AOD-9604 is far superior to liquid pre-made solutions — lyophilised powder retains potency for years in frozen storage, while liquid preparations degrade within weeks even when refrigerated.
Order AOD-9604 — ships to Batrad
COA-verified · International tracking · Research grade
As a research compound, AOD-9604 has not been through the clinical trial process required for pharmaceutical approval — its safety profile is characterised by preclinical data and limited human studies. Reconstitute AOD-9604 with bacteriostatic water at the concentration suited to your research design; a standard 5mg reconstituted in 2mL produces 2.5mg/mL — or 25mcg per insulin syringe unit. Bacterial endotoxin contamination is the greatest safety hazard associated with research-grade peptides — verify endotoxin testing is included in the batch-specific COA before any injectable research application. PubMed represent the most comprehensive research databases for AOD-9604 research; favour indexed journal publications over preprints over unreviewed preprints or forum reports.
Frequently Asked Questions
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
